Some of the intermediate-risk patients with normal karyotype were refined as the favorable risk ones in the revised 2016 WHO classification of AML because they had the prognostically favorable alteration, biallelic CEBPA (biCEBPA) mutations, compared with patients with wild-type or monoallelically mutated CEBPA (4, 5). This evidence concerns the gene CEBPA and acute myeloid leukemia.